Health Care • Biotechnology: Pharmaceutical Preparations
$58.51 ▲ +1.02
(+1.77%)
MKT CAP: $11.33B • VOL: 2.27M
52W L $49 52W H $71
BMRN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.22B | $2.85B | $2.42B |
| YoY Revenue Growth % | +12.9% | +18.0% | — |
| Gross Profit | $2.50B | $2.27B | — |
| Gross Margin % | 77.7% | 79.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $409.5M | $484.2M | $185.8M |
| Operating Margin % | 12.7% | 17.0% | 7.7% |
| Net Income (GAAP) | $348.9M | $426.9M | $167.6M |
| EBITDA (Normalized) | $491.9M | $552.6M | $272.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $828.0M | $572.8M | $159.3M |
| Capital Expenditures (CapEx) | $103.0M | $85.4M | $108.9M |
| Free Cash Flow (FCF) | $725.0M | $487.4M | $50.4M |
| FCF Margin % | 22.5% | 17.1% | 2.1% |
| Return on Invested Capital (ROIC %) | 6.0% | 7.2% | 4.0% |
| Cash & Short-Term Equivalents | $1.31B | $942.8M | — |
| Total Debt (Short + Long Term) | $597.2M | $598.9M | $1.43B |
| Total Stockholders' Equity | $6.09B | $5.66B | $2.94B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BMRN.